Our RADAR signature program sets new standards for imaging core labs
Imaging Endpoints is pleased to introduce its exclusive RADAR Signature Program. We leverage advanced imaging techniques to RApidly Detect and Assess Response (RADAR) in order to evaluate drug activity early. RADAR is designed to measure response within one or two dosing cycles, and RADAR signatures have predicted response as early as 8 hours following the first cycle of treatment.
How does the RADAR signature program work?
Our advanced imaging technologies assist clients in uncovering diverse biologic associations using standard non-invasive imaging modalities such as CT, MRI and PET. This enables you to track and monitor a particular targeted therapy at a molecular level, leading to a deeper, richer evaluation, and ultimately a more effective trial design. Our services and technologies allow us to provide you with more sophisticated information about your development program, and ultimately your therapy, without affecting data capture workflow.
The RADAR signature program can be essential when used in early product development:
- GO, NO-GO and “GO WHERE” decisions
- Deep analysis of ALL measurable subject lesions in early stage trials including quantification of biological response
- Integration of novel imaging with biologic data to correlate activity
- Development of predictive response signatures (imaging biomarkers)
- Identification of optimal target/subjects for improved trial design
What imaging techniques are used?
Other imaging core labs are not able to utilize critical information inherently present on CT and MRI scans acquired as part of standard-of-care imaging. Imaging Endpoints’ proprietary software and specialists capture pixel-level data to quantify biological response beyond size.
- Scans generally obtained through standard-of-care imaging
- Advanced techniques include biologic, textural and pharmacodynamic imaging methods
- State-of-the-art technology and expert affiliations in radiogenomics
How are RADAR signatures generated?
The RADAR Signature information is generated internally as well as through an exclusive arrangement with TexRAD (for Quantitative Textural Analysis) and close partnerships with leading institutions like Scottsdale Healthcare Research Institute, TGEN and other academic thought leaders that apply their advanced processes within the compliant controls of our imaging core lab.
What is TexRAD and Quantitative Textural Analysis (QTA)?
QTA is a post-processing technique that can be used to quantify changes in tissue heterogeneity, cellularity, perfusion, hypoxia and other parameters by assessing the distribution of textural features within a tumor lesion and its change following treatment. QTA reduces the effect of photon noise and probes the biological diversity inherent in tumor complexity. QTA can quantify a range of measurable parameters based on enhancement characteristics and density changes on a pixel-by-pixel basis. The system and platform required for measuring texture complexity is exclusively available at Imaging Endpoints’ Core Lab through a strategic partnership with TexRAD (University of London, Sussex).
Quantitative Textural Analysis (QTA) is a novel analysis platform that measures density/intensity on a pixel-by-pixel basis. QTA creates a profile of pixel signal intensity over an area of interest on standard of care Images
- Filter out photon noise
- Measure of signal intensity (SI) of each individual pixel
- Cluster pixels of similar SI together
- Mathematical transformation of histogram profile
- Representation of tumor morphology
- Characterization of tissue response and biology
QTA Quantitates:
- Heterogeneity
- Perfusion
- Hypoxia
- Other biological changes that may be indicative of response
QTA may be performed from standard of care CT, MRI, PET or Mammography scans
- Backed by nearly 40 publications in leading journals
- Has been shown to be more predictive of response than RECIST or Choi
- Has been used to develop imaging biomarkers that predict response from baseline scans
The future of imaging
Whether it is tumor blood flow or radiogenomics, Imaging Endpoints is at the leading edge of imaging science and is redefining the role an imaging core lab can provide in product development. It is one more way that Imaging Endpoints helps you “Connect Imaging to the Cure”!
